Adapting to a pandemic - conducting oncology trials during the SARS-CoV-2 pandemic - Articles - Oncology · Hematology

COVID-19

Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2

Ann Oncol.

Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, Morganti S, Passerini R, Orecchia R, Curigliano G

doi: 10.1016/j.annonc.2020.10.473.

COVID-19

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic

No abstract available

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

COVID-19

[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]

Rev Med Suisse

Jankovic J, Da Silva Lopes AM, Morez A, Darnac C, Demicheli R, Dalla-Vale M, Lauriers N, Garcia Sanchez J, Bouchaab H, Ninane F, Peters S, Michielin O, Pradervand S, Eicher M, Colomer-Lahiguera S

COVID-19

SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic

J Clin Oncol.

Berghoff AS, Gansterer M, Bathke AC, Trutschnig W, Hungerländer P, Berger JM, Kreminger J, Starzer AM, Strassl R, Schmidt R, Willschke H, Lamm W, Raderer M, Gottlieb AD, Mauser NJ, Preusser M

doi: 10.1200/JCO.20.01442.

Breast CancerEndocrine and Neuroendocrine Tumors (NET)Gastrointestinal CancerGenitourinary CancerGynecologic CancerHead and Neck CancerLung, Respiratory and Thoracic CancerSarcomaMyeloproliferative Neoplasms (MPNs)

What is the significance of the conjunctiva as a potential transmission route for SARS-CoV-2 infections?

Ophthalmologe.

Lange C, Wolf J, Auw-Haedrich C, Schlecht A, Boneva S, Lapp T, Agostini H, Martin G, Reinhard T, Schlunck G

doi: 10.1007/s00347-020-01255-7.

COVID-19

Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients

Br J Haematol

Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, Gasser K, Petrausch U, Fraunberger P, Hartmann B, Winder T

doi: 10.1111/bjh.17743

COVID-19

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

Eur J Cancer.

Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, Cassier P, Eberst L, Steineur MP, Kazes M, Perol M, Michallet AS, Rey P, Erena-Penet AS, Morel A, Brahmi M, Dufresne A, Tredan O, Chvetzoff G, Fayette J, de la Fouchardiere C, Ray-Coquard I, Bachelot T, Saintigny P, Tabutin M, Dupré A, Nicolas-Virelizier E, Belhabri A, Roux PE, Fuhrmann C, Pilleul F, Basle A, Bouhamama A, Galvez C, Herr AL, Gautier J, Chabaud S, Zrounba P, Perol D, Blay JY

doi: 10.1016/j.ejca.2020.05.028.

SPECIAL REPORT

Multiple Myeloma (MM)Further PublicationsCOVID-19

Related content

Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic

Recent Developments in Metastatic Breast Cancer

[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]

SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic

What is the significance of the conjunctiva as a potential transmission route for SARS-CoV-2 infections?

Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

Treating MM-Patients During the COVID-19 Pandemic: An Interview with Prof. Maria-Victoria Mateos